脂蛋白相关磷脂酶A2与冠状动脉斑块特征相关分析

目的探讨冠心病患者血清脂蛋白相关磷脂酶A2(Lp-PLA2)与冠状动脉斑块特征的关系。方法回顾性分析2015年7月至2016年7月郑州大学第五附属医院和第一附属医院心血管内科行冠状动脉造影(CAG)检查和血管内超声(IVUS)检查的冠心病患者165例,根据IVUS结果分为稳定斑块组86例和易损斑块组79例,比较2组患者生化指标、IVUS指标和Lp-PLA2水平,分析Lp-PLA2水平与斑块特征的相关性。采用SPSS 17.0统计软件对数据进行分析。组间比较采用t检验或χ2检验,单因素分析采用Pearson直线相关分析,logistic回归分析影响斑块稳定的危险因素。结果易损斑块组相比稳定斑块组斑块负荷[(58.20±13.59)%vs(54.72±9.98)%]、血管重塑指数[(1.61±0.32)vs(1.13±0.26)]、斑块偏心指数[(1.58±0.15)vs(1.48±0.36)]和坏死组织[(25.1±9.9)%vs(12.3±7.5)%]以及钙化组织[(6.5±3.5)%vs(0.8±0.4)%]所占比例增高,纤维帽厚度[(0.60±0.27)vs(0.75±0.31)mm]、纤维化脂质组织[(17.0±5.6)%vs(20.2±6.1)%]和纤维组织[(59.9±7.5)%vs(62.2±7.1)%]比例降低,差异具有统计学意义(P0.05)。Lp-PLA2水平与斑块成分中坏死组织(r=0.514)、斑块负荷(r=0.395)、血管重塑指数(r=0.832)、斑块偏心指数(r=0.904)成正相关,与纤维帽厚度(r=-0.710)成负相关,差异具有统计学意义(P0.05)。斑块稳定性的危险因素为高血压(OR=6.82,95%CI2.16~21.46,P=0.01)、糖尿病(OR=2.65,95%CI 1.02~6.74,P=0.04)、吸烟史(OR=1.25,95%CI 1.06~1.62,P0.01)、低密度脂蛋白胆固醇(OR=1.36,95%CI 1.10~1.76,P0.01)、Lp-PLA2(OR=10.69,95%CI 1.72~66.91,P=0.001)。结论 Lp-PLA2水平可作为评估冠状动脉斑块是否稳定的敏感指标。     

急性冠脉综合征与脂蛋白相关磷脂酶A2的相关性

目的 探讨急性冠脉综合征患者血清脂蛋白相关磷脂酶A2（Lp-PLA2）的水平及其对预后的临床价值.方法 入选急性冠脉综合征（ACS）患者112例,分为不稳定型心绞痛（UA）组、急性心肌梗死（AMI）组和非ST段抬高型心肌梗死（NSTEMI）组,其中UA组根据危险度分层分为低危、中危和高危组;对照组78例.所有患者均行冠状动脉造影检查,采用Gensini积分方法对各支冠状动脉病变程度进行评定,用ELISA方法测定各组Lp-PLA2水平,进行对比分析.结果 ACS各组患者血清Lp-PLA2水平均显著高于对照组（P＜0.01）;AMI组Lp-PLA2水平显著高于UA组（P＜0.01）;高危、中危组Lp-PLA2水平均高于低危组（P＜0.01,P＜0.05）,且三组相对应的冠脉评分也随着危险度的升高而增加（P＜0.01）.结论 Lp-PLA2水平可作为预测ACS病情严重程度及预后的重要生化指标之一.     

脂蛋白相关磷脂酶A2与冠状动脉病变的关系

目的:对冠心病患者进行冠脉造影检查,并测定其血浆中脂蛋白相关磷脂酶A2(LP-PLA2)的水平,以探讨LP-PLA2与各型冠心病的病变支数、狭窄程度及斑块稳定程度的关系.方法:将入选收住本院的患者分四组,急性心肌梗死组51例,不稳定性心绞痛组48例,稳定性心绞痛组54例,冠脉造影正常者44例为对照组.入选冠心病患者的确诊依据世界卫生组织诊断标准和中华医学会的相关指南.所有患者均接受冠脉造影检查,同时采集血标本.用酶联免疫吸附(ELISA)法分别测定四组患者LP-PLA2浓度.所得数据使用SPSS统计软件处理,以P<0.05作为差异有统计学意义.结果:①在急性心肌梗死组、不稳定性心绞痛组、稳定性心绞痛组三组中的男性,高血压和吸烟史的比例较对照组高,稳定性心绞痛组和不稳定性心绞痛组高血压的发生率高于急性心肌梗死组,差异均有统计学意义(P均<0.05).②急性心肌梗死组高敏C反应蛋白,基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶抑制剂-1(T1MP-1)以及新喋呤均高于对照组、不稳定性心绞痛组及稳定性心绞痛组,差异均有统计学意义(P均＜0.05).③在稳定性心绞痛组和不稳定性心绞痛组中LP-PLA2水平较对照组高,差异有统计学意义(P<0.05),④各组内随着病变支数的增加,LP-PLA2的水平有逐步升高趋势,但差异无统计学意义.在病变支数相同时,各组之间进行比较差异无统计学意义(P均>0.05).将病变支数相同的患者合并结果显示:随着病变支数增加,LP-PLA2水平逐步升高,多支病变明显高于单支病变,差异有统计学意义(P<0.01).随着冠脉病变的支数增加,LP-PLA2水平及Gensini积分呈现逐步升高趋势,3支病变与单支病变差异有统计学意义.⑤LP-PLA2的水平与高敏C反应蛋白(R=0.02,P=0.82)、新喋呤(R=-0.11,P=0.14)、MMP-9(R=-0.15、P=0.40)以及TIMP-1(R=0.12,P=0.11)皆无相关性.结论:LP-PLA2的水平与冠脉的病变支数有着密切关系,可以在一定程度上反应冠脉的狭窄程度.LP-PLA2与冠脉粥样硬化和斑块稳定与否的关系,仍需进一步的实验评估.     

脂蛋白相关磷脂酶A2与冠状动脉粥样硬化的关系

脂蛋白相关磷脂酶A2(Lp-PLA2)是一种主要由成熟的巨噬细胞和淋巴细胞合成和分泌,在血浆中主要与低密度脂蛋白结合,参与粥样斑块形成的起始、发展和稳定性丧失以及最终破裂的各个阶段,是目前心血管事件中新的独立预测因子[1].     

脂蛋白相关磷脂酶A2与冠心病

脂蛋白相关磷脂酶A2(Lp-PLA2)是冠状动脉粥样硬化过程中一种重要的炎症标志物,大量的临床研究提示其对冠心病的进展有预测价值,也与斑块特征相关.Lp-PLA2特异性高,很少受其他炎症标志物影响,为临床筛选高风险人群提供新途径,也为冠心病的治疗提供新靶点.     

冠状动脉慢血流病人血浆脂蛋白相关磷脂酶A2的变化及其临床价值

目的探讨血浆脂蛋白相关磷脂酶A2 (Lp-PLA2)水平与冠状动脉慢血流(CSF)的关系,以及老年与非老年CSF病人的临床特点。方法本研究共纳入65例经冠状动脉造影证实的CSF病人(CSF组)和60例冠状动脉血管及血流正常的病人(对照组),并分别根据年龄分为老年组和非老年组。采用校正的心肌梗死溶栓治疗血流记帧法计数(TFC)测定冠状动脉血流速度,测定并比较2组血生化指标和Lp-PLA2水平。结果老年CSF病人中,女性病人比例明显高于非老年组(P=0. 006)。与相应对照组相比,老年CSF组和非老年CSF组病人Lp-PLA2水平明显升高(P<0. 05),左前降支、左回旋支和右冠状动脉的心肌梗死溶栓治疗TFC和平均TFC均显著更高(P<0. 001)。随着CSF涉及的冠状动脉数量的增加,Lp-PLA2的水平逐渐增加。Logistic回归分析显示,LpPLA2是老年CSF(OR=1. 019,95%CI:1. 002～1. 037,P<0. 05)和非老年CSF(OR=1. 015,95%CI:1. 000～1. 030,P<0. 05)共同的独立预测因素。结论 ...     

脂蛋白相关磷脂酶A2与冠状动脉粥样硬化性心脏病

脂蛋白相关磷脂酶A2(Lp-PLA2)与冠状动脉斑块的稳定性相关,已成为冠状动脉粥样硬化性心脏病（冠心病）的独立预测因子。Lp-PLA2可预测急性冠脉综合征（ACS）,评估经皮冠状动脉介入治疗（PCI）患者的预后。虽然Lp-PLA2抑制剂达普拉缔（Darapladib）Ⅲ期临床试验效果不佳,但目前研究发现运动及他汀类药物能降低Lp-PLA2水平。该文介绍Lp-PLA2的性质和对冠心病相关的预测价值及目前降低Lp-PLA2的方法。     

脂蛋白相关磷脂酶A2水平与冠状动脉病变严重程度的关系

目的 探讨脂蛋白相关磷脂酶A2(Lp-PLA2)水平与冠状动脉(冠脉)病变严重程度的相关性.方法 检测344例疑诊为冠状动脉疾病(CAD)患者血浆Lp-PLA2,并行冠脉造影,以病变支数及评分评价冠脉病变程度,并分析与Lp-PLA2水平之间的关系.结果 无CAD者(冠脉评分=0分)与CAD者Lp-PLA2水平差异有统计学意义[(211±47)ng/ml与(245+59)ng/m1](u=5.99,P＜0.05);不同冠脉病变支数、冠脉评分与Lp-PLA2水平闻差异有统计学意义,3支病变和2支病变组均高于1支病变组[(254±66)ng/ml、(247+57)ng/ml和(230±50)ng/m1](F=9.98、H=29.09,均P＜0.05);在排除影响因素后,经多元逐步回归分析显示,Lp-PLA2是冠脉病变的危险因子.结论 血浆Lp-PLA2水平与冠状动脉病变呈正相关.     

急性冠状动脉综合征患者血清血栓调节蛋白和脂蛋白相关磷脂酶A2水平变化及临床意义

目的:检测急性冠状动脉综合征(ACS)患者血清血栓调节蛋白(TM)及脂蛋白相关磷脂酶A2(Lp-PLA2)水平变化及临床意义。方法:入选冠心病患者120例,分为ACS组69例和稳定性心绞痛(SAP)组51例。再将120例冠心病患者按病变血管支数分为单支病变组(45例)、双支病变组(38例)和3支病变组(37例)。采用Gensini评分系统评定冠状动脉血管病变狭窄程度,按Gensini积分分为轻度病变组(<26分)36例、中度病变组(26~54分)48例和重度病变组(>54分)36例。另选同期有胸痛症状CTA正常的患者20例为对照组。用酶联免疫吸附试验(ELISA)法分别检测血清TM、Lp-PLA2水平。结果:与对照组比较,SAP组、ACS组血清TM、Lp-PLA2水平均明显升高;与SAP组比较,ACS组血清TM、Lp-PLA2均明显升高。单支病变组、双支病变组及3支病变组血清TM、Lp-PLA2均差异无统计学意义。重度病变组血清TM水平明显高于中度病变组和轻度病变组(均P<0.05)。轻度病变组、中度病变组和重度病变组血清Lp-PLA2均差异无统计学意义(P>0.05)。ACS组患者血清TM和Lp-PLA2间呈正相关,而SAP组和对照组间无相关。结论:ACS患者血清TM和Lp-PLA2均升高,说明炎性反应及内皮功能损伤参与了ACS的发病过程,并且两者可能有协同作用。     

脂蛋白相关磷脂酶A2与原发性高血压的相关性

目的：研究原发性高血压（EH）患者血清脂蛋白相关磷脂酶A2（Lp-PLA2）水平的变化,探讨其变化在EH中的可能作用。方法：选择EH患者60例,其中高血压1级组患者20例,≥2级组20例,≥2级合并冠心病组20例。另选择健康体检者20例作为正常对照组。用酶联免疫吸附（ELISA）法检测定各组血清Lp-PLA2活性。结果：高血压≥2级合并冠心病组、≥2级组及1级组血清Lp-PLA2水平[（92.53±9.71）μg/L、（86.92±9.61）μg/L、（77.94±8.03）μg/L]均明显高于正常对照组[（71.30±5.99）μg/L],P〈0.05～〈0.01。多元线性逐步回归分析显示血清Lp-PLA2水平与收缩压、舒张压呈正相关（r=0.678,0.503,P均〈0.01）,亦与低密度脂蛋白胆固醇水平呈正相关（r=0.519,P〈0.01）。结论：血清脂蛋白相关磷脂酶A2水平与高血压的严重程度相关,可能参与高血压的发生、发展过程。     

Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome

Objective

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a vascular-specific inflammatory enzyme, of which increases are associated with cardiovascular events. However, the relationship between circulating Lp-PLA2 levels and coronary plaque volume has not been clarified in patients with acute coronary syndrome (ACS).

Methods

We studied 40 patients with ACS (age, 61.4 ± 8.0 years; male, 87.5%; statin use, 45.0%) who had undergone successful percutaneous coronary intervention (PCI). Plaque volume (PV) in non-culprit sites of PCI lesions was precisely determined using grayscale intravascular ultrasound (IVUS) at onset and at six months later. We then analyzed associations among PV, lipid profiles and Lp-PLA2 levels.

Results

Circulating Lp-PLA2 levels and PV significantly decreased between baseline and six months of follow-up (458.6 ± 166.7 IU/L vs. 378.4 ± 158.5 IU/L, p < 0.001 and 82.2 ± 34.8 mm³ vs. 77.3 ± 33.1 mm³, p < 0.001, respectively). The % change in PV positively and significantly correlated with % change in LDL-C and in the LDL-C/HDL-C ratio (r = 0.444, p = 0.004 and r = 0.462, p = 0.003, respectively). Furthermore, % changes in Lp-PLA2 and in PV correlated even more closely (r = 0.496, p = 0.001). The absolute change in PV also significantly correlated with the change in Lp-PLA2 levels (r = 0.404, p = 0.009).

Conclusions

Circulating Lp-PLA2 levels are associated with changes in coronary plaque determined by IVUS in patients with ACS.     

脂蛋白相关磷脂酶A2与临床冠心病的关系

目的探讨冠心病患者血清脂蛋白相关磷脂酶A2(Lp-PLA2)与冠状动脉(冠脉)炎症反应程度的关系。方法102例经冠脉造影证实的患者纳入冠心病(CHD)组,其中稳定型心绞痛(SAP)41例,不稳定型心绞痛(UAP)30例,急性心肌梗死(AMI)31例,对照组38例为冠脉造影正常的非冠心病者。所有对象造影前采集血标本以检测Lp-PLA2、C反应蛋白(CRP)和白细胞介素6(IL-6)。结果(1)冠心病组血清Lp-PLA2、CRP和IL-6均高于对照组(P<0.01);(2)AMI组与UAP组血清Lp-PLA2、CRP、IL-6比较差异无显著性(P>0.05),但均高于SAP组(P<0.01),在校正了心血管危险因素后差异仍有统计学意义;(3)经双变量相关性分析,血清Lp-PLA2水平与CRP、IL-6水平呈显著相关(r=0.722、0.665,P<0.01)。结论血清Lp-PLA2水平能反映冠脉炎症活动性状况,对冠心病的病情判断有一定价值。     

The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that belongs to the superfamily of phospholipase A2 enzymes. Although initial studies showed that Lp-PLA2 might be protective against atherosclerosis, emerging data seem to suggest that Lp-PLA2 may be proatherogenic, which is an effect thought to be mediated by lysophosphatidylcholine and oxidized nonesterified fatty acids, two mediators generated by Lp-PLA2. This article reviews the potential mechanisms by which Lp-PLA2 may participate in the pathogenesis of atherosclerosis and its clinical manifestations, namely, coronary artery disease and stroke.     

Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses

BACKGROUND: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an emerging cardiovascular risk marker. To explore the biologic role of Lp-PLA2 in atherosclerosis, we examined its expression and contribution to leukocyte activation under proatherogenic conditions. METHODS AND RESULTS: Following the induction of diabetes and hypercholesterolemia in a porcine model, a rapid increase in plasma Lp-PLA2 activity was observed at 1 month. This was accompanied by upregulated Lp-PLA2 mRNA expression by peripheral blood mononuclear cells (PBMC) at 3 months, and elevated Lp-PLA2 mRNA expression in coronary arteries at 6 months. These changes were paralleled by increased inflammatory responses by circulating PBMC (ICAM-1, IL-6), in coronary tissues (ICAM-1, VCAM-1), and the subsequent accumulation of inflammatory cells. In human PBMC, proinflammatory mediators augmented the synthesis and release of functional Lp-PLA2. Furthermore, lysophosphatidylcholine (lysoPC), a product of Lp-PLA2 activity, induced an increase in several inflammatory cytokines (IL-1beta, IL-6, TNF-alpha) in a concentration-dependent manner. In contrast, Lp-PLA2 inhibition (SB677116; 1 microM) abrogated the inflammatory response elicited by oxidized LDL. CONCLUSIONS: In an experimental model of diabetes and hypercholesterolemia, leukocyte activation was associated with augmented Lp-PLA2 expression. In vitro, Lp-PLA2 activity mediated leukocyte activation and inflammatory responses, whereas Lp-PLA2 inhibition abolished inflammatory responses induced by oxidized LDL. Collectively, these observations support a proatherogenic role for Lp-PLA2.     

脂蛋白相关性磷脂酶A2活性与冠心病的关系

目的:探讨血浆脂蛋白相关性磷脂酶A2(Lp-PLA2)活性与冠心病(CHD)传统危险因素的关系及与CHD发病的关系。方法:测定经冠状动脉造影证实的87例CHD患者和58例对照组的血浆Lp-PLA2活性、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平并进行比较;同时调查年龄、性别、高血压史、糖尿病史、高脂血症史及吸烟史等CHD危险因素,研究它们与Lp-PLA2活性的关系。结果:①CHD组血浆Lp-PLA2活性显著高于对照组(P<0.01)。②CHD组中男性并高脂血症者Lp-PLA2活性显著升高。血浆Lp-PLA2活性与TC、LDL-C呈正相关,与HDL-C呈负相关,而与年龄、高血压、糖尿病、吸烟、TG无关。③非条件Logistic多元回归分析显示,调整其他危险因素后,Lp-PLA2活性仍与CHD独立相关。结论:CHD患者血浆Lp-PLA2活性显著增高,与TC、LDL-C呈正相关,与HDL-C呈负相关,是CHD的独立危险因素。     

The correlation between lipoprotein-associated phospholipase A2 and severity of coronary artery diseases

正Objective To investigate the relationship between lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and the severity of coronary artery diseases.Meth-o dsA case-control study was conducted to select 231 patients with positive coronary angiography results in Beijing Huaxin Hospital. They were divided into two groups(untreated goup:147 cases; the medication group:84